Pharmaceuticals can have significant environmental implications, and therefore require an Environmental Risk Assessment (ERA). This entails a thorough examination of the fate and potential hazards posed by these compounds.
However, this process can be highly involved and may take significant time.
Our team comprises highly expert study directors with a wealth of experience in analytical methods, environmental fate, and ecotoxicology.
We ensure that we are well-prepared to meet and exceed regulatory expectations and keep up to date with evolving guidelines and modifications to existing ones in both the US and EU.
We offer a number of studies to the pharmaceutical industry, including:
Acute and Chronic studies
Freshwater and marine
Chronic Daphnia & FELS
Higher Tier simulation